0001225208-14-023001.txt : 20141110
0001225208-14-023001.hdr.sgml : 20141110
20141110163624
ACCESSION NUMBER: 0001225208-14-023001
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20141110
FILED AS OF DATE: 20141110
DATE AS OF CHANGE: 20141110
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Merck & Co. Inc.
CENTRAL INDEX KEY: 0000310158
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 221918501
STATE OF INCORPORATION: NJ
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: ONE MERCK DRIVE
STREET 2: P.O. BOX 100
CITY: WHITEHOUSE STATION
STATE: NJ
ZIP: 08889-0100
BUSINESS PHONE: 908-423-1000
MAIL ADDRESS:
STREET 1: ONE MERCK DRIVE
STREET 2: P.O. BOX 100
CITY: WHITEHOUSE STATION
STATE: NJ
ZIP: 08889-0100
FORMER COMPANY:
FORMER CONFORMED NAME: SCHERING PLOUGH CORP
DATE OF NAME CHANGE: 19920703
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: FRAZIER KENNETH C
CENTRAL INDEX KEY: 0001181175
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-06571
FILM NUMBER: 141209163
MAIL ADDRESS:
STREET 1: ONE MERCK DRIVE
STREET 2: P.O. BOX 100
CITY: WHITEHOUSE STATION
STATE: X1
ZIP: 08889-0100
4
1
doc4.xml
X0306
4
2014-11-10
0000310158
Merck & Co. Inc.
MRK
0001181175
FRAZIER KENNETH C
ONE MERCK DRIVE
WHITEHOUSE STATION
NJ
08889-0100
1
1
Chairman, President & CEO
Common Stock
2014-11-10
4
M
0
9333.0000
35.0900
A
350878.0630
D
Common Stock
2014-11-10
4
M
0
3542.0000
31.8400
A
354420.0630
D
Common Stock
2014-11-10
4
S
0
10000.0000
57.9784
D
344420.0630
D
Common Stock - 401(k) Plan
3519.0523
I
By 401(k)
Stock Option (right to buy)
31.8400
2014-11-10
4
M
0
3542.0000
0.0000
D
2006-02-25
2015-02-24
Common Stock
3542.0000
14164.0000
D
Stock Option (right to buy)
35.0900
2014-11-10
4
M
0
9333.0000
0.0000
D
2007-03-03
2016-03-02
Common Stock
9333.0000
37332.0000
D
The exercise and sale transactions reported in this Form 4 are made pursuant to a Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $57.7100 to $58.2300, inclusive. The reporting person undertakes to provide to Merck & Co., Inc., any security holder of Merck & Co., Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above in this footnote.
Holdings include shares acquired in dividend reinvestment transactions.
Includes shares acquired and dividends earned through October 7, 2014, in the Merck U.S. Savings Plan, a 401(k) plan.
The option became exercisable in equal installments on 2/25/2006, 2/25/2007 and 2/25/2008.
The option became exercisable in equal installments on 3/3/2007, 3/3/2008 and 3/3/2009.
Katie Fedosz as Attorney-in-Fact for Kenneth C. Frazier
2014-11-10